Pharma's investment in a patient is largely complete before the first dose. Realization Yield is the yield on that investment, and yield is a leadership choice rather than a market condition.
Patient support consulting that rebuilds the operating model and attaches a measure to it. Eight manufacturer audit, Realization Yield, and a routing design for the patient.
Eight manufacturers publish up to nine affordability routes each. None publishes a tool telling a patient which one is hers. The router is a phone number.
Three kinds of firm answer to the words pharma CX and none governs whether generated value survives. The questions to ask, and what Consumer-Grade demands.
Twenty defined terms from one pharma commercial practice, from Consumer-Grade to Realization Yield, including two that disagree with general business usage.
Synthetic personas generate the hypothesis, direct voice tests recognition, the frontline confirms occurrence. Run in that order the three compound. Run alone each produces no decision.
The chain starts with the science and ends with patient therapy. The clinical decision is the pivot point, and it depends on the commercial model rather than sitting after it.
Channel coordination makes outbound activity consistent. Journey coordination makes a customer's progress continuous. Only the second is Consumer-Grade.
Access is used loosely to mean coverage, and coverage is one of six barrier classes. A usable taxonomy, and why where a barrier stalls matters more than what type it is.
